MXPA00010367A - Composiciones de levosimendan perorales de liberacion controlada. - Google Patents
Composiciones de levosimendan perorales de liberacion controlada.Info
- Publication number
- MXPA00010367A MXPA00010367A MXPA00010367A MXPA00010367A MXPA00010367A MX PA00010367 A MXPA00010367 A MX PA00010367A MX PA00010367 A MXPA00010367 A MX PA00010367A MX PA00010367 A MXPA00010367 A MX PA00010367A MX PA00010367 A MXPA00010367 A MX PA00010367A
- Authority
- MX
- Mexico
- Prior art keywords
- levosimendan
- composition
- release
- drug
- further characterized
- Prior art date
Links
- WHXMKTBCFHIYNQ-SECBINFHSA-N levosimendan Chemical compound C[C@@H]1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-SECBINFHSA-N 0.000 title claims abstract description 92
- 229960000692 levosimendan Drugs 0.000 title claims abstract description 92
- 239000000203 mixture Substances 0.000 title claims description 112
- 238000013270 controlled release Methods 0.000 title claims description 19
- 239000002207 metabolite Substances 0.000 claims description 35
- 229940079593 drug Drugs 0.000 claims description 34
- 239000003814 drug Substances 0.000 claims description 34
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 17
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 17
- 230000002035 prolonged effect Effects 0.000 claims description 16
- 239000000783 alginic acid Substances 0.000 claims description 15
- 235000010443 alginic acid Nutrition 0.000 claims description 15
- 229920000615 alginic acid Polymers 0.000 claims description 15
- 229960001126 alginic acid Drugs 0.000 claims description 15
- 150000004781 alginic acids Chemical class 0.000 claims description 15
- 238000004090 dissolution Methods 0.000 claims description 15
- 239000008363 phosphate buffer Substances 0.000 claims description 15
- 239000000843 powder Substances 0.000 claims description 15
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 14
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 14
- 238000000338 in vitro Methods 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 12
- 229920000642 polymer Polymers 0.000 claims description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 11
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 11
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 11
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 11
- -1 fatty acid ester Chemical class 0.000 claims description 8
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 210000002429 large intestine Anatomy 0.000 claims description 5
- 235000019871 vegetable fat Nutrition 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 11
- 238000011282 treatment Methods 0.000 abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- WHXMKTBCFHIYNQ-UHFFFAOYSA-N 2-[[4-(4-methyl-6-oxo-4,5-dihydro-1h-pyridazin-3-yl)phenyl]hydrazinylidene]propanedinitrile Chemical compound CC1CC(=O)NN=C1C1=CC=C(NN=C(C#N)C#N)C=C1 WHXMKTBCFHIYNQ-UHFFFAOYSA-N 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 37
- 235000021355 Stearic acid Nutrition 0.000 description 15
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 15
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 15
- 239000008117 stearic acid Substances 0.000 description 15
- 230000036470 plasma concentration Effects 0.000 description 12
- 239000002775 capsule Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 239000002253 acid Substances 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- 208000010496 Heart Arrest Diseases 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000007903 gelatin capsule Substances 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 229960001681 croscarmellose sodium Drugs 0.000 description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 4
- 239000008240 homogeneous mixture Substances 0.000 description 4
- 229920001477 hydrophilic polymer Polymers 0.000 description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 229920003091 Methocel™ Polymers 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 3
- 239000008173 hydrogenated soybean oil Substances 0.000 description 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000013563 matrix tablet Substances 0.000 description 3
- 208000018316 severe headache Diseases 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000002553 single reaction monitoring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- DUXYWXYOBMKGIN-UHFFFAOYSA-N trimyristin Chemical compound CCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCC DUXYWXYOBMKGIN-UHFFFAOYSA-N 0.000 description 2
- PVNIQBQSYATKKL-UHFFFAOYSA-N tripalmitin Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- JJNZXLAFIPKXIG-UHFFFAOYSA-N 2-Chlorobenzylidenemalononitrile Chemical compound ClC1=CC=CC=C1C=C(C#N)C#N JJNZXLAFIPKXIG-UHFFFAOYSA-N 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001440269 Cutina Species 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920003096 Methocel™ K100M Polymers 0.000 description 1
- 229920003095 Methocel™ K15M Polymers 0.000 description 1
- 229920003094 Methocel™ K4M Polymers 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 240000006661 Serenoa repens Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Detergent Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI980901A FI980901A7 (fi) | 1998-04-23 | 1998-04-23 | Levosimendaania säädellysti vapauttavia oraalisia koostumuksia |
| PCT/FI1999/000329 WO1999055305A2 (en) | 1998-04-23 | 1999-04-23 | Controlled release peroral compositions of levosimendan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA00010367A true MXPA00010367A (es) | 2002-06-04 |
Family
ID=8551575
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA00010367A MXPA00010367A (es) | 1998-04-23 | 1999-04-23 | Composiciones de levosimendan perorales de liberacion controlada. |
Country Status (37)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI20011465A0 (fi) * | 2001-07-04 | 2001-07-04 | Orion Corp | Pyridatsinonijohdannaisen uusi käyttö |
| WO2004082615A2 (en) * | 2003-03-14 | 2004-09-30 | Nirmal Mulye | A process for preparing sustained release tablets |
| FI20070521A7 (fi) * | 2006-11-10 | 2008-05-11 | Atacama Labs Oy | Rakeita, tabletteja ja rakeistusmenetelmä |
| EP2306823A4 (en) | 2008-06-30 | 2012-09-26 | Tocagen Inc | 5-FLUOROCYTOSINE FORMULATIONS AND USES THEREOF |
| JP2014172850A (ja) * | 2013-03-07 | 2014-09-22 | Capsugel Belgium Nv | ハードカプセル製剤 |
| CN105784895B (zh) * | 2015-10-30 | 2018-05-22 | 成都欣捷高新技术开发有限公司 | 一种用高效液相色谱仪检测左西孟旦中杂质的方法 |
| JP2023507626A (ja) | 2019-12-16 | 2023-02-24 | テナックス・セラピューティクス，インコーポレイテッド | 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ203684A (en) | 1982-04-05 | 1986-06-11 | Merck Sharp & Dohme | Granular formulation for the stabilization of unstable drugs or food supplements |
| US4716042A (en) | 1986-06-16 | 1987-12-29 | American Home Products Corporation | Stabilized coated aspirin tablets |
| GB8903130D0 (en) * | 1989-02-11 | 1989-03-30 | Orion Yhtymae Oy | Substituted pyridazinones |
| GB2251615B (en) * | 1991-01-03 | 1995-02-08 | Orion Yhtymae Oy | (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile |
| US5213811A (en) * | 1991-09-13 | 1993-05-25 | Sterling Drug Inc. | Oral sustained-release drug compositions |
| GB2266841A (en) * | 1992-05-06 | 1993-11-17 | Orion Yhtymae Oy | Compounds for use as anti-ischemic medicaments |
| US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| GB9614098D0 (en) | 1996-07-05 | 1996-09-04 | Orion Yhtymae Oy | Transdermal delivery of levosimendan |
| FI973804A7 (fi) | 1997-09-26 | 1999-03-27 | Orion Yhtymae Oy | Levosimendaanin oraalisia koostumuksia |
| FI974578L (fi) * | 1997-12-19 | 1999-06-20 | Orion Yhtymae Oyj | Menetelmä levosimendaanin antamiseksi |
| FI980902A7 (fi) * | 1998-04-23 | 1999-10-24 | Orion Yhtymae Oyj | Levosimendaanin stabiileja koostumuksia |
-
1998
- 1998-04-23 FI FI980901A patent/FI980901A7/fi unknown
-
1999
- 1999-03-26 CO CO99018533A patent/CO5070607A1/es unknown
- 1999-04-09 TW TW088105661A patent/TWI224507B/zh not_active IP Right Cessation
- 1999-04-22 AR ARP990101869A patent/AR019096A1/es active IP Right Grant
- 1999-04-23 BR BR9909869-5A patent/BR9909869A/pt not_active Application Discontinuation
- 1999-04-23 CZ CZ20003780A patent/CZ295194B6/cs not_active IP Right Cessation
- 1999-04-23 GE GEAP19995639A patent/GEP20032906B/en unknown
- 1999-04-23 TR TR2000/03102T patent/TR200003102T2/xx unknown
- 1999-04-23 WO PCT/FI1999/000329 patent/WO1999055305A2/en not_active Ceased
- 1999-04-23 CA CA002329234A patent/CA2329234C/en not_active Expired - Fee Related
- 1999-04-23 SK SK1554-2000A patent/SK285427B6/sk not_active IP Right Cessation
- 1999-04-23 JP JP2000545505A patent/JP4566402B2/ja not_active Expired - Fee Related
- 1999-04-23 AU AU35246/99A patent/AU756641B2/en not_active Ceased
- 1999-04-23 AT AT99916941T patent/ATE258425T1/de not_active IP Right Cessation
- 1999-04-23 UA UA2000116616A patent/UA68376C2/uk unknown
- 1999-04-23 DE DE69914472T patent/DE69914472T2/de not_active Expired - Lifetime
- 1999-04-23 PL PL344078A patent/PL197447B1/pl not_active IP Right Cessation
- 1999-04-23 MX MXPA00010367A patent/MXPA00010367A/es unknown
- 1999-04-23 US US09/673,794 patent/US7045147B1/en not_active Expired - Fee Related
- 1999-04-23 ID IDW20002367A patent/ID27987A/id unknown
- 1999-04-23 HU HU0101458A patent/HUP0101458A3/hu unknown
- 1999-04-23 PT PT99916941T patent/PT1071397E/pt unknown
- 1999-04-23 RS YUP-639/00A patent/RS49962B/sr unknown
- 1999-04-23 DK DK99916941T patent/DK1071397T3/da active
- 1999-04-23 NZ NZ507453A patent/NZ507453A/xx unknown
- 1999-04-23 EE EEP200000617A patent/EE04220B1/xx not_active IP Right Cessation
- 1999-04-23 EA EA200001098A patent/EA002829B1/ru not_active IP Right Cessation
- 1999-04-23 IL IL13895199A patent/IL138951A0/xx active IP Right Grant
- 1999-04-23 KR KR1020007011788A patent/KR100960597B1/ko not_active Expired - Fee Related
- 1999-04-23 CN CNB998064181A patent/CN1248691C/zh not_active Expired - Fee Related
- 1999-04-23 EP EP99916941A patent/EP1071397B1/en not_active Expired - Lifetime
- 1999-04-23 ES ES99916941T patent/ES2215379T3/es not_active Expired - Lifetime
- 1999-04-23 HR HR20000704A patent/HRP20000704B1/xx not_active IP Right Cessation
- 1999-04-23 SI SI9930536T patent/SI1071397T1/xx unknown
-
2000
- 2000-10-11 IL IL138951A patent/IL138951A/en not_active IP Right Cessation
- 2000-10-12 ZA ZA200005632A patent/ZA200005632B/en unknown
- 2000-10-20 NO NO20005313A patent/NO329809B1/no not_active IP Right Cessation
- 2000-11-17 BG BG104959A patent/BG64839B1/bg unknown
-
2010
- 2010-01-12 JP JP2010004367A patent/JP2010083900A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100712032B1 (ko) | 신규한 페노피브레이트 갈레노스 제제의 제조방법, 제조된갈레노스 제제 및 용도 | |
| JPH07558B2 (ja) | モピダモール製剤 | |
| JP2005508901A (ja) | 活性成分を徐放する剤形 | |
| JP2010083900A (ja) | レボシメンダンの制御放出経口用組成物 | |
| KR20050085978A (ko) | 고형 발사르탄 약제학적 조성물 | |
| US20250248987A1 (en) | Pharmaceutical compositions of cabozantinib | |
| US20120039963A1 (en) | 3-(2-Dimethlaminomethyl Cyclohexyl)Phenol Retard Formulation | |
| US20050238715A1 (en) | Developing a delivery system for multi-pharmaceutical active materials at various release rates | |
| WO2005011642A9 (en) | Single unit pharmaceutical composition comprising a mixture of a fibrate and an homocysteine reducing agent | |
| HK1034032B (en) | Controlled release peroral compositions of levosimendan | |
| JP2016503782A (ja) | Ｎ−［５−［２−（３，５−ジメトキシフェニル）エチル］−２ｈ−ピラゾール−３−イル］−４−［（３ｒ，５ｓ）−３，５−ジメチルピペラジン−１−イル］ベンズアミドの医薬製剤 | |
| KR20010093186A (ko) | 프로펜 함유 제약 혼합물 |